PCN116 - Budget Impact Analysis of Panobinostat – Bortezomib and Dexamethasone, As 3rd Or 4th Line of Treatment in Patients with Relapsed/Refractory Multiple Myeloma in Greece
| Autor: | Vellopoulou, K, Kourlaba, G, Delimpasi, S, Chatzikou, M, Katodritou, E, Konstantopoulou, K, Megalakaki, K, Pouli, A, Repousis, P, Terpos, E |
|---|---|
| Zdroj: | In Value in Health November 2016 19(7):A729-A729 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect